A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
An Open-label, Dose Escalation Phase 1 Study to Investigate HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2, in Patients With Advanced Solid Tumors Refractory to Standard Therapy
Sponsor: Henlix, Inc
Terminated
Lack of efficacy
Listed as NCT03494231, this PHASE1 trial focuses on Solid Tumor, Adult and remains terminated or withdrawn. Sponsored by Henlix, Inc, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henlix, Inc
For direct contact, visit the study record on ClinicalTrials.gov .